Inclusion-body myositis associated with Sjögren's disease: clinical characteristics and comparison with other Sjögren-associated myositis.

ESSDAI Sjögren’s disease connective tissue diseases inclusion body myositis inflammatory myopathy

Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
01 Mar 2024
Historique:
received: 10 11 2023
revised: 19 01 2024
accepted: 07 02 2024
medline: 2 3 2024
pubmed: 2 3 2024
entrez: 2 3 2024
Statut: aheadofprint

Résumé

To describe the characteristics of patients with Sjögren's disease (SjD) and inclusion-body myositis (IBM), and how they compare to SjD patients with other inflammatory myopathies (IM). Patients were retrospectively recruited from 13 French centers and included if they met the ACR/EULAR criteria for SjD and for IM. They were categorized as SjD-IBM if sub-criteria for IBM were met, or as SjD-other IM if not. SjD-IBM patients (n = 22) were mostly females (86%), with a median [Q1; Q3] age of 54 [38.5; 64] years at SjD diagnosis, and 62 [46.5; 70] years at first IBM symptoms. Although most patients displayed glandular and immunological abnormalities, additional extra-glandular manifestations were uncommon, resulting in moderate disease activity at SjD diagnosis (ESSDAI 5.5 [1; 7.8]). Classic IBM features were frequent, such as progressive symptom onset (59%), asymmetrical (27%) and distal (32%) involvements, dysphagia (41%), low CPK (386.5 [221.8; 670.5] UI/l) and CRP (3.0 [3; 8.5] mg/l) levels. Immunosuppressants were reported as efficient in 55% of cases.Compared with SjD-IBM patients, SjD patients with other IM (n = 50) were significantly younger, displayed more frequent additional extra-glandular disease, higher ESSDAI score (11 [3; 30]), shorter delay between SjD diagnosis and myositis onset (0 [-0.5; 26]), more frequent CPK values over 1000 UI/l (36%), and less frequent classic IBM features. IBM can occur in SjD patients, with muscle features reminiscent of classic sporadic IBM characteristics, but mostly affecting women. In SjD patients with muscle involvement, extra-glandular manifestations, high ESSDAI score, elevated CPK values, and shorter delay after SjD diagnosis plead against IBM.

Identifiants

pubmed: 38430004
pii: 7617730
doi: 10.1093/rheumatology/keae129
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Quentin Astouati (Q)

CHU Lille, Département de Médecine Interne et Immunologie Clinique, Lille, F-59000, France.
Centre National de Référence Maladies Auto-immunes Systémiques Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, F-59000, France.
Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET), Lille, F-59000, France.

Thomas Machet (T)

CHU Lille, Département de Médecine Interne et Immunologie Clinique, Lille, F-59000, France.
Centre National de Référence Maladies Auto-immunes Systémiques Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, F-59000, France.
Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET), Lille, F-59000, France.

Camille Houssais (C)

Rheumatology Department, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINOM), CHU de Brest, Brest, France.

Jean-Baptiste Noury (JB)

Reference Centre for Neuromuscular Diseases AOC, University of Brest, Brest, France.
LBAI, UMR1227, Univ Brest, Inserm, Brest, France.

Yves Allenbach (Y)

Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, APHP, Centre de Référence Maladies Neuro-Musculaires, Sorbonne University, France, Centre de Recherche en Myologie INSERM-Association Institut de Myologie, UMRS 974, Paris, France.

Laure Gallay (L)

Department of Internal Medicine and Clinical Immunology, Edouard Herriot University Hospital, Hospices Civils de Lyon, University Claude Bernard, Lyon, France.

Baptiste Quere (B)

Rheumatology Department, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINOM), CHU de Brest, Brest, France.
LBAI, UMR1227, Univ Brest, Inserm, Brest, France.

Florence Assan (F)

Laboratory of Genetic Skin Diseases, Institut Imagine, INSERM UMR 1163, Paris.

Olivier Benveniste (O)

Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, APHP, Centre de Référence Maladies Neuro-Musculaires, Sorbonne University, France, Centre de Recherche en Myologie INSERM-Association Institut de Myologie, UMRS 974, Paris, France.

Jonathan Broner (J)

Department of Internal Medicine, University Hospital of Nîmes, France.

Pierre Duffau (P)

Internal Medicine Department, Bordeaux University Hospital, FHU ACRONIM, Bordeaux, France. CNRS-UMR 5164 Immuno ConcEpT, Bordeaux University, Bordeaux, France.

Alexandra Espitia (A)

Department of Internal Medicine, Hôtel-Dieu, CHU de Nantes, France.

Anne Grasland (A)

Department of Internal Medicine, Hôpital Louis Mourier, Université Paris Cité, AP-HP, Colombes, France.

Gilles Hayem (G)

Rheumatology Department, Paris Saint-Joseph Hospital, Paris, France.

Véronique Le Guern (VL)

AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'île de France, Paris, France.

Nihal Martis (N)

Department of Internal Medicine, CHU Nice, France. Côte d'Azur University. Mediterranean Centre for Molecular Medicine, Control of gene expression (COdEX), INSERM U1065.

Kuberaka Mariampillai (K)

Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, APHP, Centre de Référence Maladies Neuro-Musculaires, Sorbonne University, France, Centre de Recherche en Myologie INSERM-Association Institut de Myologie, UMRS 974, Paris, France.

Gaëtane Nocturne (G)

Department of Rheumatology, Université Paris-Saclay, AP-HP, Hôpitaux Universitaires Paris-Saclay, Centre for Immunology of Viral Infections and Autoimmune Diseases, INSERM UMR1184, Le Kremlin Bicêtre, France.

Xavier Mariette (X)

Department of Rheumatology, Université Paris-Saclay, AP-HP, Hôpitaux Universitaires Paris-Saclay, Centre for Immunology of Viral Infections and Autoimmune Diseases, INSERM UMR1184, Le Kremlin Bicêtre, France.

Alain Meyer (A)

Department of Rheumatology, Strasbourg University Hospital, Centre de Référence des Maladies Auto-immunes Rares, Strasbourg, France.

Denis Mulleman (D)

University of Tours, EA6295 NMNS, Tours, France Department of Rheumatology, CHRU de Tours, Tours, France.

Valérie Devauchelle-Pensec (V)

Rheumatology Department, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINOM), CHU de Brest, Brest, France.
LBAI, UMR1227, Univ Brest, Inserm, Brest, France.

Aurore Collet (A)

Univ. Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, Lille, F-59000, France.
INSERM, Lille, F-59000, France.
CHU Lille, Institut d'Immunologie, Pôle de Biologie Pathologie Génétique, Lille, F-59000, France.

David Launay (D)

CHU Lille, Département de Médecine Interne et Immunologie Clinique, Lille, F-59000, France.
Centre National de Référence Maladies Auto-immunes Systémiques Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, F-59000, France.
Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET), Lille, F-59000, France.
Univ. Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, Lille, F-59000, France.
INSERM, Lille, F-59000, France.

Eric Hachulla (E)

CHU Lille, Département de Médecine Interne et Immunologie Clinique, Lille, F-59000, France.
Centre National de Référence Maladies Auto-immunes Systémiques Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, F-59000, France.
Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET), Lille, F-59000, France.

Divi Cornec (D)

Rheumatology Department, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINOM), CHU de Brest, Brest, France.
LBAI, UMR1227, Univ Brest, Inserm, Brest, France.

Dewi Guellec (D)

Rheumatology Department, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINOM), CHU de Brest, Brest, France.
LBAI, UMR1227, Univ Brest, Inserm, Brest, France.

Sébastien Sanges (S)

CHU Lille, Département de Médecine Interne et Immunologie Clinique, Lille, F-59000, France.
Centre National de Référence Maladies Auto-immunes Systémiques Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, F-59000, France.
Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET), Lille, F-59000, France.
Univ. Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, Lille, F-59000, France.
INSERM, Lille, F-59000, France.

Classifications MeSH